EMA's PRAC Meeting Reviews Key Safety Updates on Medicines

The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) held its latest meeting from August 31 to September 3, 2026, to evaluate the safety of medicines currently on the market. The committee discussed new safety information and continued their review of ongoing safety concerns.

Focus on Safety Signals

During the meeting, PRAC examined safety signals, which are information on new or incompletely documented adverse events that may be associated with a medication. The committee's role is to determine whether such signals warrant further investigation or regulatory action. Among the medicines reviewed, several were identified for additional scrutiny due to potential safety concerns.

Ongoing Evaluations

PRAC continued its evaluation of certain medicines that have been under review for safety issues. These reviews are part of the EMA's ongoing commitment to ensuring the benefits of medicines outweigh their risks. The committee reiterated the importance of monitoring adverse drug reactions and maintaining robust pharmacovigilance practices.

Recommendations and Next Steps

Following their assessments, PRAC issued recommendations for healthcare professionals and marketing authorization holders. These recommendations aim to mitigate risks and enhance the safe use of medicines. The committee's findings and advice will be forwarded to the EMA's Committee for Medicinal Products for Human Use (CHMP) for further action.

The outcomes of the PRAC meeting highlight the EMA's proactive approach to drug safety, ensuring timely interventions when necessary to protect public health. The next steps involve monitoring the implementation of PRAC's recommendations and gathering additional data to support ongoing assessments.

The next PRAC meeting is scheduled for later this year, where the committee will continue to address emerging safety issues and adapt its strategies to improve the pharmacovigilance landscape across Europe.